Treatment trajectories for Danish individuals with type 2 diabetes in the era of emerging glucose‐lowering therapies
Diabetes, Obesity and Metabolism · 2024
DOI: 10.1111/dom.15912 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Anton Pottegård und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Pharmacy, and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Sodium-Glucose Transporter 2 Inhibitors, Metformin. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk (unrestricted grant).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
To analyse patterns of glucose‐lowering therapies among people with type 2 diabetes (T2D) in Denmark from 2016 to 2023. Materials and Methods We examined time trends in the clinical profiles of people with T2D who initiated different glucose‐lowering therapy classes for the first time. We furthermore investigated individual‐level treatment trajectories following first‐ever glucose‐lowering therapy in people with or without cardiorenal disease. The study utilized data from the nationwide Danish health registries and included all individuals who filled a first‐ever prescription for metformin, dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), sodium‐glucose co‐transporter‐2 inhibitors (SGLT‐2is) or insulin, excluding those without HbA1c‐confirmed T2D or probable type 1 diabetes.
Results
We included 260 393 individuals initiating a new glucose‐lowering therapy class from 2016 to 2023, during which there were 6‐ and 3‐fold increases in initiators of GLP‐1RAs and SGLT‐2is, respectively. The median HbA1c level at treatment initiation with GLP‐1RAs or SGLT‐2is decreased, from 67‐68 mmol/mol in 2016‐2017 to 57‐58 mmol/mol in 2022‐2023. Among individuals who initiated metformin as first‐line therapy, the proportion who started additional glucose‐lowering therapy within 2 years increased from 25% in 2016 to 40% in 2021. Among the 38% of individuals who had established cardiorenal disease when they initiated first‐ever glucose‐lowering therapy in 2020, 22% used SGLT‐2is and 18% GLP‐1RAs after 2.5 years, compared with 17% and 21% among initiators without cardiorenal disease, respectively.
Conclusions
Our study documents a trend towards earlier T2D treatment intensification and an increase in the use of GLP‐1RAs and SGLT‐2is in Denmark. However, optimal T2D treatment is still not received by most individuals with early T2D and established cardiorenal disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology, Pharmacy, and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.
- Research Unit of General Practice, Department of Public Health, University of Southern Denmark, Odense and Esbjerg, Denmark.
- Clinical Research, Steno Diabetes Centre Copenhagen, Herlev, Denmark.
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University Hospital and Aarhus University, Aarhus, Denmark.
ORCID-Profile: Anton Pottegård, Lotte Rasmussen
Förderung
- Novo Nordisk (unrestricted grant)
Zitieren
APA
Pottegård, A., Andersen, J. H., Søndergaard, J., Rasmussen, L., Kildegaard, H., Vilsbøll, T., & Thomsen, R. W. (2024). Treatment trajectories for Danish individuals with type 2 diabetes in the era of emerging glucose‐lowering therapies. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15912
Vancouver
Pottegård A, Andersen JH, Søndergaard J, Rasmussen L, Kildegaard H, Vilsbøll T, et al. Treatment trajectories for Danish individuals with type 2 diabetes in the era of emerging glucose‐lowering therapies. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15912
BibTeX
@article{Pottegrd2024,
author = {Pottegård, Anton and Andersen, Jacob H and Søndergaard, Jens and Rasmussen, Lotte and Kildegaard, Helene and Vilsbøll, Tina and Thomsen, Reimar W},
title = {Treatment trajectories for Danish individuals with type 2 diabetes in the era of emerging glucose‐lowering therapies},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
doi = {10.1111/dom.15912}
}
EUVIMED